Skip to main content

Playback every public session from the inaugural 2024 Global Investors' Symposium right here on our website.

Thomas Conlon

< Back to previous page

Thomas Conlon

Chief Scientific Officer, Michelson Philanthropies and the Michelson Found Animals Foundation
Thomas Conlon

Dr. Thomas Conlon completed his undergraduate degree in genetics at Texas A&M University and his Ph.D. in genetics and biomedical studies at the University of Florida. As the Director of the University of Florida Powell Gene Therapy Center (PGTC) Toxicology Core and a member of the Pediatrics faculty, he facilitated rigorous preclinical and safety testing of gene therapy viral vectors with a special emphasis on recombinant Adeno-Associated Virus (AAV) vector. Thomas brought 14 gene therapy trials to the clinic with FDA approval for treating congestive heart failure, types of Retinal Degeneration and Glycogen Storage Diseases. He has also served industry sponsors by performing safety studies and regulatory consultations for clinical trial approval. He was the 2014 recipient of the “See the Lights” award from The Mathew Forbes Romer Foundation for excellence in the fight against children’s genetic diseases and is a member of the American Society of Gene and Cell Therapy leadership. Thomas now serves as Chief Scientific Officer for Michelson Philanthropies and the Michelson Found Animals Foundation.